




Healthcare Industry News: Pegasus
News Release - April 10, 2006
Pegasus' HeartVue 6S System Successfully Demonstrated to Cardiologists at ACC 55th Scientific Session Exposition in Atlanta
PALM BEACH GARDENS, FL--(Healthcare Sales & Marketing Network)--Apr 10, 2006 -- Pegasus/HeartView, LLC (Other OTC:PGUZ.PK ) today reports on the excellent results from the showing of its superior, non-invasive heart screening technology, the HeartVue 6S System, at the American College of Cardiology Scientific Session in Atlanta, Georgia early last month.Pegasus Pharmaceuticals holds a majority interest in HeartView, LLC, which in turn holds the worldwide patent, manufacturing and marketing rights of the HeartVue 6S System. An earlier version of this screening system has already been cleared for sale in Europe and there is a patent pending in the United States.
For corporate information, please contact Daniel P. Kesonen, Chairman & CEO of Pegasus Pharmaceuticals and HeartView, LLC at: (561) 626-9901. Email: rlk@adelphia.net. For investor information, contact Paul Davey at (778) 389-0915. Visit the Pegasus' website at: www.Pegasusbiosciences.com
Source: Pegasus Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.